Roivant Sciences LTD Form 4 insider transactions

Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 200,000 shares of common stock on July 27, 2026 for $34.95 per share.

James C Momtazee, a Director of Roivant Sciences Ltd., received 405 shares of common stock on July 17, 2026.

Melissa B Epperly, a Director of Roivant Sciences Ltd., received 543 shares of common stock on July 17, 2026.

Ilan Oren, a Director of Roivant Sciences Ltd., received 775 shares of common stock on July 17, 2026.

Roivant Sciences CEO Matthew Gline reported a transaction involving the net settlement of Restricted Stock Units (RSUs) to cover tax obligations.

Meghan Fitzgerald, a Director at Roivant Sciences, reported transactions involving the acquisition and disposition of common shares and stock options.

Roivant Sciences reports a net settlement of Restricted Stock Units (RSUs) for executive Frank Torti, involving the disposition of 40,310 common shares to cover tax obligations.

Roivant Sciences Director Mayukh Sukhatme reported a transaction involving the net settlement of Restricted Stock Units (RSUs) to cover tax obligations.

Roivant Sciences Director Melissa B. Epperly reports transactions involving the acquisition and disposition of common shares and stock options.

Roivant Sciences Director Keith S. Manchester reported a series of stock sales totaling over 1.1 million common shares between June 26 and June 30, 2026.

Roivant Sciences director Daniel Allen Gold reported the sale of 1,058,163 common shares across multiple transactions between June 26 and June 30, 2026.

QVT Financial LP reports significant transactions in Roivant Sciences Ltd. common shares, adjusting its beneficial ownership.

Roivant Sciences Ltd. director Mayukh Sukhatme reported transactions involving the acquisition and disposition of common shares and stock options.

Roivant Sciences President & Immunovant CEO Eric Venker reported transactions involving company stock, including the acquisition of options and the sale of common shares.

Roivant Sciences President Eric Venker exercised options and sold 200,000 shares while settling tax obligations.

CFO Richard Pulik disposed of 18,962 common shares to satisfy tax obligations related to RSU vesting.

Roivant Sciences President Eric Venker exercised 200,000 stock options and sold the resulting shares on April 20, 2026.

Roivant Sciences CFO Richard Pulik was granted 60,644 restricted stock units and 84,026 stock options as part of a compensation package.

Chief Accounting Officer Jennifer Humes was granted restricted stock units and stock options as part of a compensation package.

Director Ilan Oren acquired 896 common shares of Roivant Sciences Ltd. as part of director compensation, with a portion withheld for taxes.

Director Melissa B. Epperly acquired 670 common shares of Roivant Sciences Ltd. as part of the company's non-employee director compensation plan.

Director James C. Momtazee acquired 469 common shares of Roivant Sciences Ltd. as part of director compensation, with a portion withheld for taxes.

Roivant Sciences CEO Matthew Gline sold 289,774 common shares at a weighted average price of $29.16 per share.

Roivant Sciences Chief Accounting Officer Jennifer Humes reported a sale of 13,538 common shares for approximately $28.37 per share.

Roivant Sciences reports a net settlement of Restricted Stock Units (RSUs) for executive Frank Torti, impacting his beneficial ownership.

Roivant Sciences CEO Matthew Gline filed a Form 4 detailing the future conversion of capped value appreciation rights and net settlements of shares for tax obligations in March 2026.

Roivant Sciences President & CIO Mayukh Sukhatme converted Capped Value Appreciation Rights into common shares and subsequently settled tax obligations through share dispositions.

Roivant Sciences Director Meghan Fitzgerald exercised stock options and subsequently sold 70,000 common shares for a significant profit.

Roivant Sciences Ltd. CFO Richard Pulik disposed of 1,546 common shares to cover tax withholding obligations related to RSU vesting.

Roivant Sciences' Chief Accounting Officer, Jennifer Humes, disposed of 14,526 common shares to cover tax obligations related to RSU vesting.